Introduction {#Sec1}
============

Venous thromboembolism (VTE) comprises deep vein thrombosis (DVT) and pulmonary embolism (PE). Short-term (1--2 weeks) thromboprophylaxis with anticoagulants has resulted in a reduction of both non-fatal and fatal PE in medical and surgical patients \[[@CR1]--[@CR3]\]. Extended-duration regimens in surgical patients have successfully reduced the incidence of VTE compared with placebo \[[@CR4]\] or the current standard of care \[[@CR5]--[@CR9]\], and their use is recommended in clinical guidelines \[[@CR4], [@CR10]\]. Little is known about extended-duration regimens in medical patients.

Approximately three-quarters of all in-hospital deaths from PE occur in medical patients \[[@CR11]\], and the prevalence of asymptomatic and symptomatic DVT in hospitalized medical patients not receiving thromboprophylaxis is between 10 and 20% \[[@CR4]\]. Acute medical conditions, such as acute heart failure, acute infection, acute respiratory failure, stroke, and myocardial infarction, are known to put patients at increased risk of VTE \[[@CR12], [@CR13]\], and most conditions that require prolonged immobilization also represent a temporary excess risk of VTE \[[@CR12]\]. Other risk factors include age over 75 years, chronic heart failure, cancer and chemotherapy, prior VTE, obesity, varicose veins, and thrombophilia \[[@CR12]--[@CR16]\].

Large randomized clinical trials that have demonstrated the effectiveness of short-term pharmacologic thromboprophylaxis in acutely ill medical patients showed reductions in the relative risk of VTE of between 45 and 64% \[[@CR2], [@CR17]--[@CR19]\]. The results of these trials formed the basis of guideline recommendations for the use of unfractionated heparin, low-molecular-weight-heparins (LMWHs), or fondaparinux in this patient population \[[@CR4]\].

Although guidelines recommend anticoagulant use in acutely ill medical patients, their use is not routine in clinical practice. International registry and epidemiological data have shown that approximately 50% of at-risk acutely ill medical patients receive any form of prophylaxis, and that less than 40% receive prophylaxis in line with recommendations from the American College of Chest Physicians (ACCP) guidelines \[[@CR20], [@CR21]\].

There is evidence that the risk of VTE in acutely ill medical patients persists beyond hospital discharge. In the MEDENOX study, where prophylaxis or placebo were administered for 10 ± 4 days, eight venous thromboembolic events (7.8% of the total) occurred between days 15 and 110, of which four were fatal PEs \[[@CR17]\]. More recently, the EXCLAIM study demonstrated that extended-duration enoxaparin (38 ± 4 days), compared with placebo after open-label standard-duration enoxaparin (10 ± 4 days), significantly reduced the overall incidence of VTE (absolute risk difference, −1.53% \[95.8% confidence interval \[CI\], −2.54 to --0.52%\]) in acutely ill medical patients with reduced mobility, but with a significant increase in the incidence of major bleeding (absolute risk difference, 0.51% \[95% CI, 0.12 to 0.89%\]) \[[@CR22]\].

Rivaroxaban is an oral, direct Factor Xa inhibitor approved in many countries worldwide for the prevention of VTE after elective hip and knee replacement surgery in adult patients. Rivaroxaban has a fast onset and offset of action, and has been shown to have predictable pharmacokinetics (PK) and pharmacodynamics (PD) and a low propensity for drug--drug interactions \[[@CR23]\].

MAGELLAN (Multicenter, rAndomized, parallel Group Efficacy and safety study for the prevention of VTE in hospitalized acutely iLL medical patients comparing rivaroxabAN with enoxaparin) was designed to assess both the efficacy and safety of oral rivaroxaban compared with standard-duration subcutaneous (s.c.) enoxaparin, and to evaluate the role of extended-duration (approximately 5 weeks) thromboprophylaxis in acutely ill medical patients.

Study objectives {#Sec2}
================

The objectives of the study are twofold: firstly, to determine whether oral rivaroxaban 10 mg once daily (od) for 10 ± 4 days is non-inferior to s.c. enoxaparin (40 mg od) for 10 ± 4 days for the prevention of VTE in patients aged 40 years or older and hospitalized for a medical illness; secondly, to determine whether oral rivaroxaban 10 mg od for 35 ± 4 days is superior to s.c. enoxaparin 40 mg od for 10 ± 4 days (placebo continued until day 35 ± 4), in the same patient population. The principal safety objective is to compare the safety of rivaroxaban administered for 35 ± 4 days with enoxaparin administered for 10 ± 4 days.

Methods {#Sec3}
=======

Study design {#Sec4}
------------

MAGELLAN is a prospective, randomized, blinded (patient, care-giver, data-collector, and outcome-assessor), double-dummy, active comparator-controlled, multicenter, multinational clinical trial in acutely ill medical patients. The trial is being conducted in accordance with the Declaration of Helsinki and local regulations. Approval of the protocol was obtained from the appropriate ethics committee or institutional review board for all participating centers.

Setting {#Sec5}
-------

As of July 2010, 8,101 patients have been randomized in 556 centers from 52 countries (Table [1](#Tab1){ref-type="table"}).Table 1Number of sites enrolled by participating countriesGeographic region and countriesNumber of sites enrolledAfrica: total14 South Africa14Asia: total121 China43 Hong Kong2 India14 Indonesia3 Japan32 Korea7 Malaysia3 Pakistan3 Singapore6 Taiwan5 Thailand3Australia and New Zealand: total14 Australia11 New Zealand3Europe: total278 Austria14 Belgium10 Bulgaria8 Croatia6 Czech Republic7 Denmark5 Estonia4 Finland2 France22 Germany27 Greece10 Hungary8 Israel10 Italy21 Latvia6 Lithuania10 Luxembourg2 The Netherlands4 Norway4 Poland14 Portugal10 Russia8 Slovakia5 Slovenia6 Spain11 Sweden9 Switzerland6 Turkey6 Ukraine16 United Kingdom7North America: total97 Canada13 Mexico12 United States72South America: total32 Argentina7 Brazil8 Chile2 Colombia8 Peru7

Patients {#Sec6}
--------

Subjects are considered for enrollment if they are hospitalized for a specified acute medical illness, have a risk of VTE (reduced mobility with conditions as specified in inclusion criteria; Table [2](#Tab2){ref-type="table"}), and their anticipated survival time is more than 6 months. Patients with acute infectious, inflammatory, or rheumatic diseases, and those with acute respiratory insufficiency, also require one or more well-characterized risk factors for VTE, such as a history of VTE or cancer \[[@CR16], [@CR24], [@CR25]\]. All patients are required to give written informed consent. Patients are excluded from the study if they have conditions that contraindicate the use of enoxaparin or rivaroxaban. Patients are also excluded if they have certain concomitant conditions or diseases, including conditions that may increase the risk of bleeding, or if they require certain drugs or procedures (examples listed in Table [2](#Tab2){ref-type="table"}).Table 2Principal inclusion and exclusion criteria for MAGELLANInclusion criteriaExclusion criteriaPatients aged ≥40 yearsConditions that contraindicate the use of the LMWH enoxaparinPatients at risk of venous thromboembolic events being hospitalized for acute medical conditions as follows:\
  Heart failure, NYHA class III or IV\
  Active cancer (e.g. admitted for chemotherapy or for treatment of a complication of the active cancer)\
  Acute ischemic stroke\
  Acute infectious and inflammatory diseases, including acute rheumatic diseases\
  Acute respiratory insufficiency\
Patients with at least one additional risk factor for VTE:\
  Severe varicosis\
  Chronic venous insufficiency\
  History of cancer\
  History of DVT or PE\
  History of heart failure NYHA class III or IV\
  Thrombophilia (hereditary or acquired)\
  Recent major surgery (6--12 weeks)\
  Recent serious trauma (6--12 weeks)\
  Hormone replacement therapy\
  Advanced age ≥75 years\
  Morbid obesity (body mass index ≥35 kg/m^2^)\
  Acute infectious disease contributing to hospitalization\
Additional risk factor not required for patients with:\
  Heart failure NYHA class III/IV with previous hospitalizations for heart failure NYHA class III/IV or chronic NYHA class III/IV status\
  Active cancer\
  Acute ischemic stroke with lower extremity paresis or paralysis\
Anticipated complete immobilization^a^ for ≥1 day during the hospitalization and anticipated decreased level of mobility^b^ for ≥4 days after randomization in any type of care setting (e.g. hospital, intermediate care or rehabilitation centre, managed care in home, etc.) and additional anticipated ongoing decreased mobility^c^ thereafter\
Hospitalized \<72 h before randomizationBleeding risk-related criteria:\
  Clinically significant bleeding, within 30 days of randomization\
  Major surgery, biopsy of a parenchymal organ, ophthalmic surgery, or serious trauma within 6 weeks before randomization\
  A presenting diagnosis for which surgery is intended during hospitalization\
  Known coagulopathy or bleeding diathesis or an INR \>1.5 at the time of screening unrelated to VKA therapy\
  History of hemorrhagic stroke at any time in the past, evidence of primary intracranial hemorrhage on CT or MRI scan of the brain, or clinical presentation consistent with intracranial hemorrhage\
  Recent severe head trauma within 30 days of randomization\
  Known intracranial neoplasm, cerebral metastases, arteriovenous malformation, or aneurysm\
Concomitant conditions or diseases, such as:\
  Known allergy to rivaroxaban or any of its excipients\
  Severe renal insufficiency\
  Known significant liver or LFT abnormalities that would require study medication discontinuation\
  Known HIV infection at screening\
  Sustained uncontrolled systolic blood pressure of ≥180 mmHg or diastolic pressure of ≥100 mmHg at time of screening despite treatment\
  History of ongoing drug or alcohol abuse\
  Cardiogenic or septic shock with the need for vasopressor(s)\
  Pregnancy or breastfeeding or any plan to become pregnant during the study\
Required drugs or procedures, such as:\
  \>2 days of prophylactic use of anticoagulants\
  Systemic treatment with more than two doses of strong inhibitors of cytochrome P450 3A4, such as ketoconazole or protease inhibitors, within 4 days before randomization or planned treatment during the time period of study drug administration\
  Indication for fibrinolysis or need for continued treatment with anticoagulant agents for more than 14 days\
  Treatment with or use of mechanical thromboprophylaxis (e.g. pneumatic compression devices, foot pumps) for VTE prevention*CT* computed tomography, *DVT* deep vein thrombosis, *HIV* human immunodeficiency virus, *INR* international normalized ratio, *LFT* liver function test, *LMWH* low-molecular-weight-heparin, *MRI* magnetic resonance imaging, *NYHA* New York Heart Association, *PE* pulmonary embolism, *VKA* vitamin K antagonist, *VTE* venous thromboembolism^a^Complete immobilization: the patient is totally confined by his or her illness to bed or chair. The patient may be allowed to use a bedside commode or with assistance may be allowed bathroom privileges^b^Decreased mobility: immobilization caused by the illness requiring the patient to remain in bed or chair more than 50% of the time during daytime hours^c^Ongoing decreased mobility: immobilization caused by the illness requiring the patient to remain in bed or chair during daytime hours more than was normal and usual for the patient prior to hospitalization

Treatment regimens {#Sec7}
------------------

Patients meeting the entry criteria are stratified by center using permuted blocks (size 4) and randomized using an interactive voice response system to allocate the blinded study medication. Patients are randomized to receive either s.c. enoxaparin 40 mg od for 10 ± 4 days and oral rivaroxaban placebo for 35 ± 4 days, or oral rivaroxaban 10 mg od for 35 ± 4 days and s.c. enoxaparin placebo for 10 ± 4 days. The active treatment period for the enoxaparin arm is from day 1 to day 10 ± 4 and for the rivaroxaban arm is from day 1 to day 35 ± 4 (day 1 is defined as the day of randomization). Patient follow-up continues until day 90 ± 7 (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1MAGELLAN study design. ^a^ Heart failure (New York Heart Association class III or IV), active cancer, acute ischemic stroke, acute infectious, acute inflammatory diseases or acute rheumatic diseases, or acute respiratory insufficiency. *od* once daily

Study procedures {#Sec8}
----------------

Hospital unit and ward characteristics are recorded. During the screening period, a medical history is obtained. A physical examination, an electrocardiogram, a pregnancy test for women of childbearing potential and blood sampling for clinical chemistry (electrolytes, renal and liver function, and NT-proBNP), hematology (complete blood count), and coagulation (prothrombin time, prothrombinase-induced clotting time \[PiCT^®^; Pentapharm, Basel, Switzerland\], and D-dimer) are also performed. During the baseline (day 1 visit), rivaroxaban and matching placebo are administered orally with or without food; enoxaparin and matching placebo are administered subcutaneously.

For those subjects who give informed consent for the pharmacogenetic part of the study, a blood sample for pharmacogenetic analysis is taken (a retention sample is also taken). For subjects enrolled at selected centers, and willing to participate in the full PK/PD profile part of the study, blood samples are drawn before the first dose of study medication and at 1, 2, 3, 4, 6, 9, and 12 h post-dose.

Suspected cases of DVT are evaluated by bilateral lower extremity venous ultrasonography or other vascular imaging procedures of the lower extremities, e.g. venography. Suspected cases of PE are evaluated by thoracic spiral computed tomography, a ventilation perfusion lung scan with chest X-ray, or pulmonary angiography. If the diagnosis of DVT or PE is not confirmed, subjects continue to receive study medication. Mandatory routine bilateral lower extremity venous ultrasonography is performed after the last dose of study medication or matching placebo on day 10 ± 4 and on day 35 ± 4, within 24 h of their administration. In subjects prematurely discontinuing their treatment, bilateral ultrasonography is performed at that time and at day 35 ± 4. Patients are assessed on day 90 ± 7 for adverse events, symptomatic VTE, bleeding events, acute myocardial infarction, acute ischemic stroke, and death. Clinical chemistry is also performed for liver function testing. Symptoms of DVT or PE occurring during follow-up are verified by appropriate diagnostic testing as described above.

Efficacy and safety outcomes {#Sec9}
----------------------------

There are two primary efficacy outcomes: the incidence of the composite of asymptomatic proximal DVT, symptomatic DVT (proximal or distal), symptomatic non-fatal PE, and VTE-related death from day 1 to day 10 + 4 (test for non-inferiority); and the incidence of this composite outcome from day 1 to day 35 + 4 (test for superiority).

The secondary efficacy outcomes are the incidence of the composite of asymptomatic proximal DVT, symptomatic DVT, symptomatic non-fatal PE, and all-cause mortality up to day 10 + 4 and day 35 + 4 (major secondary outcome); symptomatic VTE up to day 10 + 4, day 35 + 4, and day 90 + 7; and all-cause mortality up to day 90 + 7. Net clinical benefit will be assessed by the composite outcome of asymptomatic proximal DVT, symptomatic DVT, symptomatic non-fatal PE, VTE-related death, treatment-emergent major bleeding, and non-major clinically relevant bleeding up to day 10 + 4 and day 35 + 4. The incidence of each component of the primary efficacy outcomes and the composite of cardiovascular death, acute myocardial infarction, or acute ischemic stroke up to day 10 + 4, day 35 + 4, and day 90 + 7 are also secondary outcomes.

The primary safety outcome is the incidence of the composite of treatment-emergent major bleeding and non-major clinically relevant bleeding observed not later than 2 days after the last intake of study medication. Bleeding events are defined in Table [3](#Tab3){ref-type="table"}. Bleeding events observed more than 2 days after the last intake of study medication will be considered separately. Minimal bleeding events, i.e. any other overt bleeding episodes not meeting the criteria for major bleeding or non-major clinically relevant bleeding events, will also be summarized. Other safety outcomes include treatment-emergent adverse events and abnormal laboratory parameters.Table 3Definitions of bleeding eventsDefinitionMajor bleeding \[[@CR42]\] Bleeding leading to a ≥2 g/dl fall in hemoglobin or a transfusion of ≥2 units of packed red blood cells or whole blood Bleeding into a critical site (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or Bleeding leading to deathNon-major clinically relevant bleeding Overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact with a physician, temporary cessation of study treatment or discomfort for the subject such as pain, or impairment of activities of daily life Examples include:  Any bleeding compromising hemodynamics  Any bleeding leading to hospitalization  Subcutaneous skin hematoma \>25 cm^2^ or 100 cm^2^ if provoked  Intramuscular hematoma  Epistaxis (lasting \>5 min), if it is repetitive or leads to an intervention  Gingival bleeding if it occurs spontaneously or if it lasts \>5 min  Hematuria if it is macroscopic and either spontaneous or lasts for \>24 h after instrumentation (e.g. catheter placement or surgery) of the urogenital tract  Macroscopic gastrointestinal hemorrhage: at least one episode of melena/hematomesis, if clinically apparent and hemoccult positive  Rectal blood loss, if more than a few spots on toilet paper  Hemoptysis, if more than a few speckles in the sputum and not occurring within the context of pulmonary embolism  Any other type of bleeding that is considered to have clinical consequences for a patient

PK and PD parameters {#Sec10}
--------------------

A target of 125 patients willing to participate in a full PK/PD profile will be stratified into five groups of 25 patients for the major diagnostic groups.

Based on the plasma concentration--time data, PK parameters of rivaroxaban will be calculated on day 1 and day 10 ± 4 for the data-rich profile obtained in this subset of patients. These parameters include area under the curve, maximum concentration of drug in plasma, elimination half-life, and apparent clearance.

Pharmacogenetics {#Sec11}
----------------

The pharmacogenetic assessment allows analysis of genes involved in the absorption, distribution, metabolism, and excretion of the study drug. Genes involved in coagulation, thrombotic diseases, treatment response, and safety could also be evaluated. No prospective analyses are planned for the pharmacogenetic samples in the study, and samples will be stored and analyzed only if other data collected in the study result in a hypothesis that can be tested by genetic analysis.

Health economics outcome research {#Sec12}
---------------------------------

Healthcare resource utilization is evaluated and includes primary hospitalization type and duration, re-hospitalization and emergency room visits, healthcare professional visits, outpatient surgery and consultations, and need for inpatient or outpatient rehabilitation or skilled nursing facility stay. Quality of life measures (EQ-5D \[European Quality of Life\] questionnaire) and patient-reported outcomes (SF-12 \[Short Form\] survey) are also being collected.

Statistical analyses and sample size {#Sec13}
------------------------------------

A statistical analysis plan has been completed. Subjects are valid for the safety analysis if at least one dose of study medication is administered. Two efficacy analysis populations are defined, both for the non-inferiority analysis and for the superiority analysis. In both populations, patients are eligible for the modified intention-to-treat (mITT) analysis if they are valid for the safety analysis and have an adequate assessment of VTE, defined as an adequate assessment of DVT or PE, if applicable. Patients are eligible for the per-protocol analysis if they are valid for the mITT analysis, have an adequate assessment of VTE performed not later than 2 days after the last intake of study drug, meet the inclusion criteria, and have no major protocol violations.

Sensitivity analyses will be performed for the primary efficacy endpoint considering all randomized subjects. A method described for the analysis of a binary composite endpoint with missing data in components will be used \[[@CR26]\]. The two components of the binary composite endpoint will be the assessment of an asymptomatic proximal DVT from the bilateral lower extremity venous ultrasonography and the assessment of symptomatic lower extremity DVT (proximal or distal), symptomatic non-fatal PE, or VTE-related death. The latter assessment will be considered to have been evaluated in all subjects because it is assumed that such an event would have been reported if it occurred. The former assessment will be considered to have been evaluated in all subjects with evaluable ultrasonography (within the assessment period). This approach derives the probabilities of the outcomes and constructs the overall rate based on the estimated probabilities of the two components. A 95% asymptotic (unstratified) confidence interval around the relative risk will be calculated.

### Efficacy analysis {#Sec14}

All statistical tests will be one-sided with a type I error rate of 2.5%; two-sided 95% CIs will be given. A multiple testing approach will be employed to evaluate the two primary efficacy outcomes \[[@CR27]\]. If the test for non-inferiority at day 10 + 4 is met, a test for superiority will be applied using the method described for the primary efficacy outcomes. If both primary outcomes are significant at the one-sided level (2.5%) then both outcomes can be declared statistically significant. If one *P*-value is greater than 2.5%, the *P*-value for the other primary outcome must be less than 1.25% before significance for this outcome can be declared.

For both primary efficacy outcomes, the relative risk ratio of the incidence rates (rivaroxaban/enoxaparin) will be estimated based on a stratified Mantel--Haenszel model (stratified by geographic region). The primary analysis population for superiority will be the mITT population. The primary analysis population for non-inferiority will be the per-protocol population.

The secondary outcomes of the composite of asymptomatic proximal DVT, symptomatic DVT, symptomatic non-fatal PE, and all-cause mortality up to day 35 + 4, and adverse events will be analyzed in the same way as the primary outcomes. The outcomes of symptomatic VTE and death will be analyzed in the safety population; the hazard ratios (rivaroxaban/enoxaparin) will be estimated based on a stratified proportional hazards model (stratified by geographic region).

### Safety analysis {#Sec15}

All statistical tests will be two-sided with a type I error rate of 5%; two-sided 95% CIs will be given. The incidence of the composite of major bleeding and non-major clinically relevant bleeding and the incidence of major bleeding will be analyzed as described for the primary efficacy outcomes. All other safety data will be analyzed descriptively.

No interim analysis was planned after the first amendment to the protocol. The introduction of the mandatory lower extremity vascular ultrasonography on day 10 ± 4 mitigated the need for an interim analysis because of a safety concern because all patients with proximal asymptomatic leg thrombosis would be identified and treated as required if detected during the day 10 ± 4 period.

### Exploratory analyses {#Sec16}

The incidence rates of the primary efficacy endpoints and the major secondary endpoint in each treatment group as well as the relative risk and the corresponding non-stratified exact two-sided 95% CIs will additionally be assessed by geographic region and country as well as by demographic variables and other covariates.

### Determination of sample size {#Sec17}

The determination of sample size takes into account the assumptions for both primary efficacy outcomes and allows for a joint power of at least 90%. A sample size of 2,876 valid patients per group was estimated based on the following assumptions: a 2.2% event rate in the control group at day 10 + 4 \[[@CR17]--[@CR19]\], a relative reduction of at least 35% in event rate with rivaroxaban at day 10 + 4, a 4% event rate in the control group at day 35 + 4 \[[@CR17]--[@CR19], [@CR28]\], a relative reduction of at least 40% in event rate with rivaroxaban at day 35 + 4, and a joint probability of a type II error of less than 10%. Assuming an invalidity rate of up to 20--30%, the total sample size of randomized subjects is 7,190--8,220. The sample size estimate assumes a non-inferiority margin of 1.5 based on the lower 95% confidence bound for the relative risk of placebo versus active treatment in a meta-analysis of three placebo-controlled trials in acutely ill medical patients \[[@CR12]\].

### PK and PD {#Sec18}

Descriptive statistics will be calculated for plasma concentration parameters. Exploratory analyses will be performed to relate coagulation parameters to bleeding events and to relate coagulation parameters to venous thromboembolic events.

Ultrasonography procedures {#Sec19}
--------------------------

To assess asymptomatic proximal DVT, bilateral ultrasonography of the proximal veins of the lower extremity is performed in all subjects. Veins identified are the common femoral vein, the deep femoral vein, the superficial femoral vein, the popliteal vein, and the trifurcation of the calf veins.

The lack of compressibility of a vein under probe pressure is considered to be the primary criterion for the demonstration of thrombosis. Compression maneuvers with the ultrasonography transducer in the transverse plane are performed at 2--3 cm intervals along the veins studied. The ultrasonography examination is adequate if all vein segments are documented by appropriately annotated continuous recordings or still images, and allows the assessment of compressibility for each of the required veins. An Ultrasonography Adjudication Committee (UAC) adjudicates all scheduled and unscheduled ultrasonographies performed during the treatment period in a blinded manner. The adjudication of the UAC is the basis for the final primary efficacy analysis.

Clinical events procedures {#Sec20}
--------------------------

A Clinical Events Adjudication Committee centrally adjudicates and/or classifies the primary and secondary efficacy and safety (all bleeding) clinical events.

Protocol amendments {#Sec21}
-------------------

Modifications to the study protocol were only implemented with agreement from both the sponsor and the Steering Committee.

After discussion with the health authorities, the following changes were made to the study protocol via its first amendment. Patients with diabetes mellitus or patients who would fall into the broad category of having 'other' medical illnesses were excluded. For patients with acute infectious, inflammatory and rheumatic diseases, and acute respiratory insufficiency, one or more additional risk factors for VTE were stipulated as a requirement for inclusion in the study. In addition, the required duration of immobilization was extended to beyond the 4 days of hospitalization, and a second routine lower extremity venous ultrasonography was added to patient assessment, performed at the time of parenteral study medication discontinuation (day 10). This efficacy outcome was to test for non-inferiority of rivaroxaban compared with enoxaparin for efficacy.

Further amendments included the addition of acute infectious disease contributing to hospitalization as an inclusion criterion and increasing the period of hospitalization before randomization from 48 to 72 h. Hospital stay and duration vary widely between countries for patients with identical admitting diagnoses and the venue of immobilization required for inclusion of a patient was expanded to any type of healthcare setting.

Current status of the study {#Sec22}
===========================

As of July 2010, 8,101 patients were included in the study and enrollment was stopped. The last patient visits took place in October 2010.

The patients cover a broad age range (40--105 years) and have a diverse range of primary diagnoses (Table [4](#Tab4){ref-type="table"}).Table 4Primary diagnosis of subjects in the MAGELLAN study safety populationSubject characteristicsNumber of subjects in the safety population7998Primary diagnosis (%)^a^ Acute infectious and inflammatory disease47.3 Acute heart failure32.4 Acute respiratory insufficiency28.0 Acute stroke17.3 Active cancer7.3 Other diseases0.7^a^Patients could have more than one primary diagnosis

Discussion {#Sec23}
==========

MAGELLAN will be the first randomized clinical trial of VTE prevention in acutely ill medical patients to directly compare rivaroxaban, a new generation oral anticoagulant, with s.c. enoxaparin administered for 10 ± 4 days. The active comparator phase of this study will allow an unbiased comparison of rivaroxaban with enoxaparin and will also provide insight into the potential benefits of oral compared with s.c. thromboprophylaxis administration.

MAGELLAN will also assess the efficacy and safety of extended-duration thromboprophylaxis with rivaroxaban. There is strong evidence for the benefits of extended-duration thromboprophylaxis in elective abdominal cancer surgery \[[@CR29], [@CR30]\] and in hip replacement \[[@CR31]--[@CR33]\] and fracture surgery \[[@CR34]\]. The use of extended-duration LMWH thromboprophylaxis up to 35 days is well established in these surgeries. Recently, oral rivaroxaban 10 mg od administered for 35 days was shown to significantly reduce the incidence of VTE in patients undergoing total hip replacement surgery compared with s.c. enoxaparin 40 mg od administered for 35 days \[[@CR5]\].

The rivaroxaban dose selected for use in the MAGELLAN study was based on phase II studies in orthopedic surgery, which demonstrated rivaroxaban 10 mg od had comparable efficacy and safety to enoxaparin 40 mg od; phase III studies confirmed this \[[@CR5], [@CR6], [@CR8], [@CR35], [@CR36]\]. The enoxaparin regimen chosen for the comparator group is approved for use in all participating countries \[[@CR37]\].

In the current study, asymptomatic VTE is diagnosed using a standardized ultrasonography protocol, as first utilized in the PREVENT study \[[@CR18]\]. The advantages of ultrasonography compared with venography are that it is convenient, readily available, non-invasive, repeatable, and does not expose patients to ionizing radiation or contrast media. Standardized ultrasonography techniques limit the sensitivity issues previously associated with ultrasonography \[[@CR38]\]. However, a consensus on standardization of venous ultrasound as an endpoint outcome is still needed \[[@CR39]\].

Risk assessment of acutely ill medical patients is important to allow physicians to prescribe appropriate anticoagulant therapy. In clinical trials of thromboprophylaxis in acutely ill medical patients, variation exists between the VTE risk factors used as patient inclusion criteria. When the MAGELLAN study protocol was designed, careful consideration was given to which VTE risk-factor-related inclusion criteria were most appropriate. Acute medical illnesses and predisposing risk factors (e.g. age or previous VTE) were selected based on published randomized controlled trials and other types of studies.

This study, which is recruiting from 52 countries and includes centers in Asia, Europe, North America, and Africa, will provide a unique opportunity to evaluate the risk of VTE and the potential benefits of extended-duration thromboprophylaxis in a truly multinational patient population.

Other than the EXCLAIM study \[[@CR40]\], MAGELLAN is the only study in this patient population (completed or ongoing) to include patients with active cancer and acute ischemic stroke---conditions associated with a high risk of VTE \[[@CR12], [@CR13]\]. Cancer in particular is a major risk factor, with up to one in five diagnosed cases of VTE occurring in a person with cancer \[[@CR41]\]. Because of the large number of patients in this study, MAGELLAN will also provide data on VTE epidemiology in subgroups of patients where there is little data, i.e. patients with acute infection or heart failure.

MAGELLAN will provide further evidence as to whether extended-duration therapy is more effective than standard-duration therapy in a diverse population of acutely ill medical patients. Furthermore, it will provide information on the efficacy, safety, and pharmacologic profile of the oral anticoagulant rivaroxaban in this patient population, as well as health economics outcome research data. Extended-duration therapy with a well-tolerated and effective oral anticoagulant given once daily has the potential to simplify thromboprophylaxis in acutely ill medical patients, particularly during the post-hospital-discharge period. This could improve patient compliance and physician adherence to guidelines, ultimately reducing VTE-associated morbidity and mortality.

Addendum {#Sec24}
========

The protocol amendments described were implemented in response to regulatory authority requests, to comply with local regulations and requirements, or to comply with labeling requirements.
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